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From structure to crystallisation and pharmaceutical 
manufacturing: the CSD in CMAC Workflows†
Lauren E. Hatcher,*a,b Ayrton J. Burgess,c Pollyanna Paynea and Chick C. Wilsona,c
Two Workflows are presented that are relevant to the design and construction of end-to-end pharmaceutiucal 
manufacturing processes.  The Workflows target the very early stage crystallisation aspect of these processes – production 
of the primary crystalline solid form – and relate to establishing decision-driven approaches for the screening for multi-
component forms, specifically co-crystals, and to the use of additives to control crystal and primary particle form, notably 
morphology.  These Workflows are shown to benefit from the use of the Million-plus structures in the Cambridge Structural 
Database and the associated structural informatics and analysis tools and are placed into the context of the work of the 
CMAC Future Manufacturing Hub.
Introduction & Context
The Focus on Optimised Pharmaceuticals Manufacturing.
Crystallisation is an integral step in the processing of 
pharmaceutical products, whose optimisation is critical in this 
context1,2, with more than 80% of market drugs being 
formulated in crystalline form. While the dominant attrition 
from initial candidate compounds to licensed and marketed 
drugs occurs in early stage synthesis, biological efficacy and 
early stage clinical testing, there is a significant element of 
“manufacturability” as a barrier to successful delivery of 
pharmaceutical products. Moreover, as the rate of discovery of 
“blockbuster” drug molecules decreases, there is an increased 
focus on improving the potential value of existing drugs or 
candidates, for example by improving formulation to enhance 
bioavailability, or by improving manufacturing processes to 
reduce costs and hence allow for more competitive product 
pricing and wider availability. Optimised and flexible 
manufacturing processes can also allow for effective 
formulation of reduced and tuneable dosage products, one 
aspect of the move towards personalised medicine approaches.
As part of this effort, in the downstream parts of the 
pharmaceuticals manufacturing chain comprehensive 
screening is essential to characterize fully the solid forms of 
each drug and their related physical properties, in order to 
assess and potentially improve the safety and effectiveness of a 
treatment. Two aspects of improving primary (crystal) solid 
forms of target APIs are discussed here: multi-component 
materials (co-crystals) and additives. These are discussed 
largely in the context of the work being carried out by the UK 
CMAC consortium, the Future Manufacturing Hub in 
Continuous Manufacturing and Advanced Crystallisation3 and 
with specific reference to the way in which tools developed by 
the Cambridge Crystallographic Data Centre (CCDC‡) are 
employed as an intrinsic element of the approaches accounted. 
The CMAC consortium tackles the issue of optimising 
pharmaceutical manufacturing by the adoption of end-to-end 
processes centred around continuous crystallisation methods4. 
The potential drivers for adoption of continuous manufacturing 
in the pharmaceutical (and fine chemicals) sector are based 
around the opportunity to optimise product quality with 
enhanced cost effectiveness, sustainability, energy and 
environmental benefits5,6. Adoption of continuous 
manufacturing approaches is also potentially well suited for 
future directions in production of small batch, targeted and 
personalised medicines. However, technical and economic 
challenges remain to be overcome to enable adoption of new 
continuous manufacturing processes, and a number of 
substantial efforts world-wide are targeting these challenges 
(for example, the Novartis-MIT Center for Continuous 
Manufacturing7). In addressing the technical challenges, CMAC 
has developed an approach based around the establishment of 
Microfactories. These are effectively constructed in a modular 
fashion from process steps, the choice and optimisation of 
which are based on an underpinning set of Workflows that can 
be implemented and linked to evaluate rapidly the feasibility of 
diverse potential approaches for the production of a given 
target molecule or family of molecules. These evaluation and 
design steps rely on a combination of experimental and digital 
approaches, to allow decision-making based on measured and 
predictive parameters. 
a.CMAC Future Manufacturing Hub, Department of Chemistry, University of Bath, 
Bath BA2 7AY, UK.
b.School of Chemistry, Cardiff University, Cardiff CF10 3AT.
c. Department of Chemistry, University of Bath, Bath BA2 7AY, UK.
† Invited paper for CrystEngComm (ACS Fall, 2019, San Diego, CSD Million Structures 
Symposium). 
Electronic Supplementary Information (ESI) available: [Workflow methodology, 
further experimental information and characterisation data]. See 
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The Cambridge Structural Database (CSD8), combining 
information available from the Million structures and more, 
together with CSD tools for analysing these, can offer an 
important informatics-based element of a digitally-driven 
approach and to the establishment of experimentally-based 
Workflows and associated decision making as part of process 
design.  Embedded in structural chemistry principles, the CSD 
offers a unique capability for establishing and analysing 
structural trends in solid state pharmaceutical materials, 
hydrogen bond patterns, target, additive and co-former 
identification. The research presented recognises the 
importance of optimisation of primary particle attributes9 and 
moves towards embedding capabilities offered by the CSD in 
pharmaceutical and fine chemical manufacturing, by 
consideration of the possibilities offered by multi-component 
crystallisation methods, which allow for application in screening 
for new solid forms with optimised physical properties, 
influencing morphology of particles for downstream processing, 
investigating the effect of additives, and more.
Multi-Component Approaches.
Multicomponent Materials. A key stage of pharmaceutical 
development is concerned with obtaining the solid form of the 
active pharmaceutical ingredient (API) that is most suitable for 
scale-up as the marketed drug product. In addition to any 
potential structural polymorphs of the pure API, solid form 
development commonly includes a screen of potential 
multicomponent (MC) materials that can be formed, which may 
display improved physical properties e.g. enhanced 
solubility/dissolution (improving bioavailability), better 
compressibility, improved particle morphology, better stability 
etc. MC materials are systems comprising of two or more 
chemically distinct molecules in the crystal lattice, typically co-
crystals. Pharmaceutical co-crystals include a neutral API 
molecule and another neutral co-former in the same crystal 
lattice, which interact with one another non-ionically via 
intermolecular interactions such as hydrogen bonds or π-π 
stacking that can be identified using crystal engineering 
methods10. Salt screens are common and have formed part of 
API solid form development for many years, whereas 
pharmaceutical co-crystals are a newer route for solid form 
manipulation whose attraction and use in the industry 
continues to grow, leading to greater attention in terms of 
regulation and guidance11.
Additive Crystallisation. Additives, inhibitors and impurities 
regularly play a crucial and often poorly-understood role in 
crystallisation processes. Despite this, many crystallisation 
routes are known that utilise additives as additional 
components offering a means of controlling the process and/or 
properties of the materials produced. As such, research and a 
more detailed understanding of the influence of additives on 
the crystallisation process is of continued scientific and 
industrial relevance12. Additives are known to influence several 
crystal particle attributes, including morphology, size and 
polymorphic form, without obvious inclusion of the additive 
into the API crystal lattice. They are also often used at very low 
additive concentrations and, in the case of polymer additives, 
can often be chosen to mirror those already used in 
downstream formulations.  Thus, the use of additives in primary 
crystallisation is of particular interest for pharmaceutical solid 
form development. One relevant physical property, often 
considered later in the processing, is the shape (morphology) of 
the primary crystals.  The morphology of a crystal largely affects 
the downstream processing steps required to produce the final 
drug product, such as filtration, drying and compaction13,14.  A 
poor morphology can often lead to extra processing steps being 
required, resulting in a more expensive process for 
pharmaceutical companies.
The key difference between MC and additive crystallisation 
routes is the intention for the incorporation of the second 
component into the API crystal structure: MC routes should only 
be considered when a change in crystal form (e.g. a co-crystal) 
is acceptable, while additive methods will be considered when 
the API must be delivered only in its pure form.  This paper 
describes standardised workflows for MC material screening 
studies and analysis, and for developing additive crystallisation 
routes on API targets within CMAC. The MC workflow is used to 
design and execute a MC material screen for the non-steroidal 
anti-inflammatory drug (NSAID) flufenamic acid, enabling us to 
benchmark the workflow and assess its suitability for MC 
material discovery, while the application of the additive 
workflow in morphology modification is illustrated for the anti-
tubercular drug isoniazid.
Experimental
Powder X-ray Diffraction.
Powder X-ray Diffraction (PXRD) data were collected on lightly 
ground samples using a STOE STADI P powder diffractometer, 
equipped with a CuKα1 source, in transmission geometry. Data 
were collected at ambient temperature, between 5 ° and 50 ° in 
2θ, using a Dectris Mythen 1K detector. The data were collected 
and analysed using the WinXPOW powder diffraction software 
suite (STOE; version 3.6.0.1).
Single Crystal X-ray Diffraction.
Single crystal X-ray diffraction (SCXRD) data were collected on a 
dual source Rigaku Oxford Diffraction Gemini A Ultra 
diffractometer, equipped with an Atlas CCD detector and an 
Oxford Cryosystems Cryojet-XL liquid nitrogen cooling device 
for temperature control. Data collection, indexing and 
integration were performed using the Rigaku Oxford Diffraction 
software CrysAlisPRO. Structures were solved by dual-space 
methods in SHELXT and refined by full matrix least squares on 
F2 in SHELXL. CH hydrogen atoms were placed geometrically and 
refined using a riding model, with isotropic displacement 
parameters fixed to Uiso = 1.2 × the Ueq of the parent atom. 
Heteroatom hydrogen atoms (OH and NH) were located from 
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the Fourier electron density difference map and refined 
isotropically).
Differential Scanning Calorimetry.
Differential scanning calorimetry (DSC) measurements were 
performed on a TA instruments Q20 calorimeter equipped with 
a Thermal Advanced Cooling System 90 and dry nitrogen purge 
gas at a flow rate of 18 mL min1. The experiments were 
controlled using the TA Instruments Advantage software, 
version 5.4.0. A lightly powdered, 5 mg sample was sealed into 
a Tzero aluminium pan and equilibrated at 20 °C, before being 
ramped to 180 °C at a heating rate of 10 °C min1. The resulting 
data were analysed in the TA Instruments Universal Analysis 
software).
Infrared Spectroscopy.
Fourier transform infrared spectroscopy (FTIR) measurements 
were performed on a Perkin Elmer FTIR spectrometer at room 
temperature, with spectra recorded on lightly ground powder 
samples between 800 and 4000 cm1. Data collection and 
analysis were performed using the Perkin Elmer Spectrum 
software, version 10.400.0190.
Workflow Development
The development of each of the MC material and Additive 
screening workflows are summarised briefly, within the context 
of the CMAC programme. Both workflows are driven by a 
decision-making process, which is based around the 
fundamental goal of accessing a new API crystal or particle form 
with one or more target physical properties that are improved 
relative to the parent compound. The workflows include regular 
checkpoint Decisions, which reflect points at which challenges 
are often encountered in a MC or additive crystallisation screen 
and a decision from the experimenter is usually required. This 
may involve situations such as poor starting material solubility, 
poor product crystallinity, a difficulty in growing single-crystals 
suitable for analysis, or issues with sample stability. The 
flowchart diagrams (Figures 1 and 2) indicate several key points 
at which the CCDC software tools, particularly those available in 
programs ConQuest and Mercury, are routinely implemented 
and these are invaluable for both experiment design and data 
analysis Stages. Key points specific to the individual workflows 
are discussed further below.
MC Material Screening Workflow.
Processes for co-crystal screening are well established in many 
laboratories; the workflow developed in the CMAC context is 
illustrated below (Figure 1).
Figure 1: CMAC Multicomponent (MC) material screening workflow. The workflow 
is driven by the decision points as indicated in the text; these capture the key 
elements indicating if the co-crystallisation process is likely to have value. Light 
blue squares indicate points at which the CCDC software tools are implemented.  
Decision 1: Is crystallinity retained following evaporation?; Decision 2: Is there 
evidence for a new product from the PXRD and DSC analysis?; Decision 3: Are 
there single crystals formed from the evaporation?; Decision 4: Is there good 
diffraction from the single crystal and can a structure be solved?; Decision 5: Is the 
product material stable to slurrying in solution?; Decision 1a: Is crystallinity 
retained after grinding?; Decision 2a: Is there evidence for a new product from the 
PXRD and DSC analysis?; Decision 3a: Is the new product pure, or is there a mixture 
of product and starting materials present?
At the start of MC material screening, the key API physical 
property targeted for improvement as a result of MC material 
development should be outlined, along with key criteria for 
success. Additionally, before experimental MC material 
screening can commence decisions on the choice of suitable co-
formers must be made. This could be achieved via a number of 
routes, as outlined in the pre-requisites section, but within 
CMAC there is a focus on the use of prediction-led screening to 
guide MC experiment design. This can include ab initio 
modelling work (both molecular and solid state), or semi-
empirical approaches such as those available from the CCDC 
software suite. The > 1 Million structures in the CSD provide a 
unique resource that should be utilised in designing a MC 
material screen, and both data mining approaches and 
molecular complementarity screening searches prove effective. 
Further details are provided in the benchmarking study below. 
Finally, any available solubility data for both the API and the 
chosen co-former set is also a valuable pre-requisite and is often 
available either from the literature or from prior experimental 
work with the pure API.
Stages 1 - 3 focus on MC materials discovery at the small 
(≤ 5 mL) scale. In practice we find that the parallel 
implementation of evaporative and mechanochemical 
crystallisation routes is an effective way to probe the maximum 
amount of the MC material design space in the shortest period 
of time. All decisions at these early stages are focussed on 
deciding if a new, crystalline product form has been accessed 
and if this can be conclusively characterised.
Stages 4 – 6 focus on MC materials development at a meso-scale 
(≤ 1 g) and the key aims of these Stages are to assess whether 
any improvement in the target physical property is achieved by 
moving to the new API solid form, and to gather other physical 
property information that will assist in the design of scaled-up 
recrystallisation routes with the new material, that will be 
pursued in accordance with other CMAC experiment workflows 
within the broader CMAC family.
The overall goal of this discovery-stage workflow is to deliver a 
new MC API crystal form, that is well-characterised at the small 
to meso-scale, in either microcrystalline powder or single 
crystal form.
Additive Screening Workflow.
In contrast to the situation for MC materials, additive 
interventions are less commonly systematically implemented.  
The Workflow developed is given in Figure 2 and includes the 
following Informatics-informed elements: Can additives offer 
benefits (in spite of being an additional process option/step); 
Which additives are likely to be effective / scalable; At what 
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level (concentration) are additive required to be used and what 
are the downstream implications.  It should be noted that for 
size matched and structurally similar additives, the two 
workflows have much commonality; co-crystal screening tends 
to focus at higher (“stoichiometric”) second component (co-
former) concentrations, while additive screening tends to focus 
on lower second component (additive) concentrations.  Any 
decisions informed by such a workflow must, of course, meet 
the key criterion of allowing decisions to be made rapidly in 
challenging process development-driven environments.
Figure 2: CMAC Additive screening workflow. The workflow is driven by the decision 
points as indicated in the text; these capture the key elements indicating if the use of 
additive crystallisation methods is likely to have value.  Light blue squares indicate points 
at which the CCDC software tools are implemented.  Decision 1: Are the chosen additives 
soluble in the solvents used for optimised non-additive API crystallisation process? (i.e. 
can a co-solvent be found easily?); Decision 2: Does the API solubility / MSZW remain the 
same in the presence of each additive candidate?; Decision 3: Does the analysis indicate 
a change in targeted property (e.g. solid-form / morphology / PSD etc.) in the presence 
of each additive candidate?; Decision 4: Does the crystallisation process chosen for the 
product proceed unchanged following a change in additive ratio?
As for the MC equivalent, at the start of an additive 
crystallisation screen the key API physical property targeted for 
improvement must be outlined, along with sensible criteria for 
success. 
The additive crystallisation screening does not aim to change 
the composition of the API material, but instead the particular 
crystal particle attributes, e.g. particle size distribution (PSD), 
shape/morphology etc. As such, there is benefit in first 
optimising the non-additive crystallisation process parameters 
with a view to employing these as a standard for all additive 
screening experiments (Stage 1, Figure 2). This helps to ensure 
any changes observed are the result of the additives, and not 
due to changes in the experiment set-up.
Stages 2 and 3 involve the choice of suitable additive candidates 
and an understanding of their solubility requirements. Within 
CMAC, as with co-former selection there is a focus on 
prediction-led approaches to additive selection and this 
includes ab initio modelling work, collaboration with the 
ADDoPT programme15, as well as empirical and semi-empirical 
approaches. Empirical routes include the collection of crystal 
face information by SCXRD face-indexing methods, which are 
beyond the scope of this article but are conducted in 
accordance with another internal CMAC workflow procedure. 
This information can be visualised in the CCDC crystal structure 
visualisation software Mercury, in conjunction with their BFDH 
morphology prediction tools. Crystal structure data from the 
CSD can also be used to understand the nature of observed and 
predicted crystal faces, included the functional groups likely at 
the crystal surface terminations and, as an extension of this, 
likely surface properties16.
Stages 4 - 5 focus on additive screening at the small (≤ 5 mL) 
scale. All decisions at these stages are focussed on determining 
whether the target crystal particle attributes has been 
enhanced, and/or confirming that there has been no change in 
the API solid form, e.g. there has been no inclusion of the 
additive into the structure, and no polymorphic phase 
transformation is induced by the presence of the additive. 
The final stages of the workflow focus on optimising the 
crystallisation conditions for the most promising additive 
candidates, including identifying the optimum additive 
concentration (Stage 6), as well as ensuring the solvent choice, 
API concentration and other crystallisation process parameters 
remain optimal for the new additive crystallisation route. All of 
this information can then inform the design of scaled-up 
additive recrystallisation routes, that will be pursued in 
accordance with other CMAC experiment workflows within the 
broader CMAC family.
The overall goal of this discovery-stage workflow is to deliver 
API crystals with enhance particle attributes, that is well 
characterised at the small scale and whose solid-form remains 
unchanged as a result of additive crystallisation.
Benchmarking the Workflows I: MC material 
screening with flufenamic acid (FLU)
The MC-Workflow was used to design a MC material screening 
experiment with flufenamic acid (FLU).  Fenamic acid 
derivatives are a class of NSAIDs that are known to display 
challenging properties for industrial recrystallisation, including 
diverse conformational polymorphism,17,18 high hydrophobicity 
and particle adhesion,19 and low aqueous solubility leading to 
reduced bioavailability.20 MC crystallisation offers a route to 
modify the crystal form, targeting improved physical properties 
and processability.
1. Workflow inputs/prerequisites.
Initial CSD data mining with ConQuest. The first step should 
determine what solid forms of FLU have already been reported, 
and this was done via a structure search in ConQuest. A similar 
search might also be performed using the WebCSD interface. 
The structure of FLU used in this investigation to search the CSD 
is given in Figure 3. The following filters were also imposed 
during the search:
 3D coordinates must be determined
 No polymeric structures
 Only organic structures.
The explicit hydrogen assignment on COOH precludes the 
return of salt structures for this search.
Figure 3: Structure of flufenamic acid (FLU), used as structure search in ConQuest, 
with all hydrogens explicitly assigned.
The search returns 22 hits, of which 10 are structure 
determinations (or re-determinations) of the eight 
characterised polymorphs of FLU (CCDC ref-code base 
FPAMCA), nine are unique MC materials and the remaining 
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three are re-determinations of these. See Table ESI-1 for further 
details.
A second search was also performed, in which an additional 
query atom (any non-metal, NM) was added to represent the 
acceptor atom of a neighbouring molecule (see Figure ESI-1). 
The Add 3D functionality was used to define both the atom label 
of this query atom, and the intermolecular contact distance 
between it and the hydroxyl oxygen. This restricted search 
allowed a quick and visual inspection of both the hydrogen bond 
acceptor atom and the intermolecular hydrogen bond distance 
in each of the returned structures. This provides valuable 
information as to the most common hydrogen bond motifs (and 
from this, infers the common supramolecular synthons) 
involved in the successful FLU-based MC materials reported to-
date. The information can then guide the choice of suitable new 
co-formers for screening. The results indicated that five of the 
nine MC structures involved OH…O hydrogen bonds, all of 
which would be classified as medium strength on the basis of 
their bond length. Closer inspection in Mercury revealed the 
majority of these to involve  COOH-dimer motifs, which is 𝑅(8)22
also the case for all of the known polymorphs of pure FLU. For 
FLU to form such a heterodimer in a MC material, there must be 
an energetic benefit over the homodimer in the pure API. This 
may reflect why only a handful of MC materials of this type are 
known. The remaining four MC structures involved medium 
strength OH…N hydrogen bonds, and closer inspection of these 
structures in Mercury revealed that these typically involved 
nitrogen atoms in aromatic ring systems.
A third search replaced the COOH group for COO- and retained 
the same filters. This returned only three organic salt structures, 
all of which are primary amine salts containing NH3+ (see Table 
ESI-2).  
Of the nine known MC structures with FLU, one of the most 
extensively studied is the FLU 4,4’-bipyridine (2:1) co-crystal 
system (with three structures reported to the CSD, ref-code 
base ZIQFEM). This, and the observed preference for FLU to 
form OH…N(aromatic) hydrogen bonds, lead us to choose its 
other common isomer, 2,2’-bypridine (CSD ref-code BIPYRL), as 
an additional co-former for our benchmarking study.
Molecular Complementarity Screening in Mercury. Within the 
CSD-Materials module of Mercury, the molecular 
complementarity screening tool tests a target API against a 
library of potential co-formers to assess the likelihood of co-
crystal formation based on a set of molecular descriptors. The 
results can then help to guide the choice of co-formers for a MC 
material screen. The five molecular descriptors, and the criteria 
for complementarity, have been chosen semi-empirically by 
previous research.21 It should be noted, however, that the 
output of the tool only suggests the likelihood of an API-co-
former match, and does not provide any information about the 
likely relative stoichiometries. This should be considered by the 
experimenter when planning their crystallisation (e.g. by 
considering the number of hydrogen bond donor and acceptor 
groups present).
The molecular descriptors can be categorised by their relation 
to either the polarity of the co-former molecule, its size, or its 
shape, as follows:
 Polarity descriptors – dipole moment magnitude, 
fraction of N and O atoms
 Size descriptor – S-axis
 Shape descriptors – S/L axis ratio, M/L axis ratio
where S = smallest molecular axis length, M = medium axis 
length, L = longest axis length. If all of the selected molecular 
descriptors meet the complementarity criteria, the molecule is 
deemed to have passed the screening test.21
The original work indicates that the polarity and shape 
descriptors are the most informative for co-former selection, 
however any of the five descriptors may be excluded from a 
search at the user’s discretion. If excluded, the descriptor is 
effectively given an automatic pass in the analysis.
Though Mercury contains its own library of potential co-
formers, for our benchmarking study we created a co-former 
library from 25 small molecules on the FDA’s Generally 
Regarded As Safe (GRAS) list22,23 (see Table ESI-3 for further 
information). If a MC material is formed between an API and a 
co-former from this GRAS library, it would prevent fewer 
regulatory concerns as a potential new drug formulation.
Three screening searches were performed with FLU and the 
GRAS library, each with a different combination of molecular 
descriptors:
 Search 1 used all five descriptors
 Search 2 used only the polarity and shape descriptors
 Search 3 used only the polarity descriptors.
Full outputs from all three searches are provided in Tables ESI-
4, ESI-5 and ESI-6. To maintain a reasonably broad design-space 
for MC material screening, the outputs of Search 3 were chosen 
to guide co-former selection. The search returned eight hits: 
adipic acid (CSD ref-code ADIPAC), benzoic acid (BENZAC), 
pyridoxine (BITZAF), octanoic acid (IZENUP), 2,4-hexadienoic 
acid (LEZHUT), nicotinamide (NICOAM), nicotinic acid (NICOAC) 
and propionic acid (PRONAC). Of these, a FLU-nicotinamide co-
crystal is already known (EXAQAW),24 and so this co-former was 
excluded. Octanoic and propionic acid were also excluded on 
the basis that – both being oily, pungent liquids – it may be 
difficult to pursue mechanochemical crystallisation 
experiments. This left a set of five GRAS co-formers 
recommended by the molecular complementarity screening for 
our study.
2. MC Workflow benchmarking.
Stage 1: Evaporative crystallisation screening. Small scale 
evaporative crystallisation experiments were set up with the 
chosen co-former set, in a selection of compatible solvents. 
10 mg of FLU powder was dissolved with a 1:1 stoichiometric 
Page 5 of 18 CrystEngComm
C
ry
st
E
ng
C
om
m
A
cc
ep
te
d
M
an
us
cr
ip
t
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
2 
Se
pt
em
be
r 2
02
0.
 D
ow
nl
oa
de
d 
on
 9
/2
3/
20
20
 2
:1
6:
29
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
DOI: 10.1039/D0CE00898B
ARTICLE Journal Name
6 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx
Please do not adjust margins
Please do not adjust margins
ratio of each co-former and dissolved in ca. 15 mL of the 
crystallisation solvent, then allowed to evaporate slowly at a 
constant 20 °C. Full experimental details are provided in the ESI.
The resulting product materials were analysed by polarised light 
microscopy (PLM) and in each case workflow Decision 1 was 
considered: is crystallinity retained? For the majority of 
samples, the answer was No and these were discarded (Table 
ESI-7), however two samples were progressed to Stage 2 of the 
workflow: [FLU + 22-BPY] from ethyl acetate, and [FLU + BA] 
from propan-2-ol.
Stage 2: Initial analysis by PXRD and DSC. The two candidate 
samples were analysed by powder X-ray diffraction (PXRD) and 
differential scanning calorimetry (DSC). The results of these 
experiments are given in Figures 4 and 5. 
For PXRD comparisons, predicted starting material patterns 
were generated from 3D crystal structure data from the CSD, 
utilising the powder prediction tool in Mercury. This capability 
is particularly useful for materials such as FLU, as any one of its 
known polymorphs might preferentially crystallise in the 
presence of the co-former additive and it is not straightforward 
to collect experimental patterns for all polymorphs simply for 
comparison purposes. For clarity, only polymorph III is included 
for comparison in Figures 4 and 5, as this was primarily 
observed, however a full comparison against all eight 
structurally characterised forms of FLU was conducted and is 
provided in the ESI.
For DSC, the experimental traces are compared to melting point 
data obtained from the literature (FLU mp = 134 °C,25 22-BPY 
mp = 72 °C,26 and BA mp = 122.4 °C.27
Figure 4: Initial analysis of [FLU + 22-BPY] evaporative crystallisation screening 
experiment. (a) Comparison of experimental PXRD data for sample with predicted 
PXRD patterns of starting materials (FLU Polymorph III and 22-BPY) from CSD 
structure data. (b) Comparison of experimental DSC data for sample with starting 
material melting point data from literature (grey dashed line = 22-BPY melting 
point, red dashed line = FLU melting point).
Comparison of the [FLU + 22-BPY] PXRD data with the starting 
materials allow us to address Decision 2 of the workflow: is 
there evidence of new forms? The analysis clearly indicates the 
production of a new crystal form, in particular from the new 
peaks identified at 11.0°, 13.8°, 15.6°, and 23.1°. Peaks at 17.0°, 
20.8° and 22.9° indicate the presence of some unreacted 22-BPY 
starting material. These results are corroborated by the DSC 
data, which show a new sharp endothermic peak at 48 °C that 
is attributed to the melt of a new crystal form, but also a small 
endotherm with an onset at 73 °C that coincides with the 
expected melt of unreacted 22-BPY. 
Decision 2 was also considered for [FLU + BA]. Again, both PXRD 
and DSC strongly indicate the presence of a new crystal form. 
The PXRD data show many new peaks, including those located 
at 6.7°, 12.8°, 15.8°, 17.8° and 18.8°, which indicate a new 
material. While there is some weak evidence of FLU form III in 
the data, there are no obvious peaks to indicate excess BA 
starting material. The DSC trace shows a sharp endotherm at 
103° that could be attributed to a new crystal form. Another, 
broader endothermic event also occurs between ~75 – 90 °C. As 
this sample was prepared from propan-2-ol, which has a boiling 
point of ~ 82 °C, this peak could represent loss of propan-2-ol 
from the powder, indicating a solvated solid form. This would 
be confirmed by a single crystal X-ray structure.
Figure 5: Initial analysis of [FLU + BA] evaporative crystallisation screening 
experiment. (a) Comparison of experimental PXRD data for sample with predicted 
PXRD patterns of starting materials (FLU Polymorph III and BA) from CSD structure 
data. (b) Comparison of experimental DSC data for sample with starting material 
melting point data from literature (grey dashed line = BA melting point, red dashed 
line = FLU melting point).
Finally, Decision 3 should be considered for both samples: are 
there single crystals? The PLM analysis of [FLU + 22-BPY] 
revealed plate-like crystals alongside the crystalline powder, 
which were suitable for analysis by SCXRD. By contrast, no 
suitable single crystals could be obtained for [FLU + BA] and, as 
per the workflow, this sample was referred for repeat 
recrystallisation attempts. To-date, no suitable single crystals 
have been prepared. Where this situation is encountered for 
high-priority materials, e.g. late-stage API candidates, more 
challenging 3D structure analysis methods could be attempted, 
e.g. structure solution from powder diffraction data. However, 
here it is outside the scope of our benchmarking investigation.
Stage 3: SCXRD analysis. SCXRD analysis was performed for a 
suitable crystal from the [FLU + 22-BPY] ethyl acetate 
recrystallisation. The unit cell obtained at the pre-experiment 
stage was compared against the CSD using the Unit Cell Search 
facility in ConQuest (or WebCSD). No known structure 
containing either starting material was returned, and a full X-ray 
data collection was completed. Full details are provided in the 
ESI.
Figure 6: Single crystal X-ray structure of FLU 22-BPY (2:1) co-crystal, showing the 
atomic connectivity with ellipsoids shown at 50 % probability. The CF3 moiety is 
disordered and is modelled over two positions, though the second component is 
omitted here for clarity. Labelled atoms are included in the asymmetric unit, with 
the remaining structure is generated by symmetry. Red dashed lines indicate 
hydrogen bonding interactions.
Table 1: Single crystal X-ray diffraction data for FLU 22-BPY (2:1) co-crystal
The data confirm that a new MC material has formed, 
containing FLU and 22-BPY in a 2:1 ratio (Figure 6). The full 
crystal data are given in Table 1. The 2:1 ratio of the product co-
crystal explains why excess 22-BPY was observed in the PXRD 
and DSC data following formation from a 1:1 stoichiometric 
ratio of starting materials. The material crystallises in the 
monoclinic space group P21/c, with one FLU molecule and half 
a 22-BPY molecule in the asymmetric unit. The N-H and O-H 
hydrogen atoms are easily located in the Fourier electron 
density difference map, with H1 clearly associated with the FLU 
molecule to retain the carboxylic acid functionality. This enables 
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the assignment of a FLU 22-BPY (2:1) co-crystal, containing one 
COOH…N intermolecular hydrogen bond between the two 
components. FTIR data, collected on a sample of ground single 
crystals, further confirm this assignment (Figure ESI-3, ESI). 
Finally, the predicted PXRD pattern for the single crystal X-ray 
structure was generated using Mercury and compared with the 
experimental data (see Figure ESI-4, ESI). There is good 
agreement between the two patterns, confirming that the 
single crystal structure is representative of the bulk sample.
At this stage we can answer Yes to Decision 4 of the workflow: 
is there good diffraction from the single crystal and can a 
structure be solved? This completes the discovery phase of the 
workflow for evaporative crystallisation routes.
Stage 1a: Mechanochemical crystallisation screening. The 
workflow diagram shows there are two discovery-level streams 
that should progress in parallel. The second of these involves 
mechanochemical, or grinding, crystallisation methods, and a 
mechanochemical crystallisation screen with FLU and the same 
co-former set was also undertaken. Given the propensity for 
fenamic acid derivatives to stick to surfaces,19 liquid assisted 
grinding (LAG) methods were employed. In a standard screening 
experiment, c.a. 15 mg of API, co-former – in a 2:1 API to co-
former ratio – and one drop of the chosen recrystallisation 
solvent, were ground by hand using a pestle and mortar for 
15 min. Full experimental details for all screens are provided in 
Table ESI-8.
The resulting powder samples were then analysed by PLM, and 
Decision 1a of the workflow was considered: is crystallinity 
retained. For several samples, the answer was Yes and these 
were progressed on to Stage 2a. Where the answer was No, 
those samples were discarded.
Stage 2a: Initial analysis by PXRD and DSC. All suitable samples 
were first analysed by PXRD to address Decision 2a: is there 
evidence of new forms? For all but one sample, the PXRD 
indicated a physical mixture of the starting materials with no 
evidence of a new material being formed. However, the 
mechanochemical screen of [FLU + 22-BPY] was successful and 
analysis of Figure 7a shows, as for the analogous evaporative 
screen, new peaks indicating the presence of the new crystal 
form [see also Figure ESI-5]. However, there is significant 
evidence of starting material peaks remaining after only 15 min 
grinding time, and a subsequent DSC experiment confirms the 
presence of significant excess 22-BPY (Figure 7b). Therefore, the 
response is No to Decision 3a of the workflow: is it pure?
Figure 7: Initial analysis of [FLU + 22-BPY] mechanochemical crystallisation 
screening experiment. (a) Comparison of experimental PXRD data for 15 min 
ground sample with predicted PXRD patterns of starting materials (FLU Polymorph 
III and 22-BPY) from CSD structure data. (b) Comparison of experimental DSC data 
for 15 min ground sample with starting material melting point data from literature 
(grey dashed line = 22-BPY melting point, red dashed line = FLU melting point).
In an attempt to access a pure MC material by 
mechanochemical routes, a second series of grinding 
experiments were then performed where the starting materials 
were ground for a total of 60 min, in a 2:1 ratio of API to co-
former. Samples were taken every 15 min and analysed by 
PXRD. The results (Figure 8) show that a near-pure sample of 
the FLU 22-BPY (2:1) co-crystal can be accessed gradually with 
longer grinding times, and a revised answer to Decision 3a is 
possible if the grinding time exceeds 60 min.
Figure 8: Formation of near-pure FLU 22-BPY (2:1) co-crystal by mechanochemical 
crystallisation methods with extended grinding times. Peaks associated with the 
22-BPY starting material are most obvious and are seen to decrease in intensity as 
grinding time increases, with no evidence of starting material after 60 min.
To investigate further this mechanochemical route to FLU 22-
BPY (2:1), the next stage would be to progress to Stage 3a and 
attempt to form the co-crystal by ball-milling. This work is 
beyond the scope of this discovery-level benchmarking 
investigation.
Stage 4: Stability testing. Once the initial crystallisation and 
characterisation phases of the workflow are complete, we move 
forward, with the best candidate sample(s), to stages that test 
a material’s suitability as a real drug formulation. Though in 
practice 22-BPY is not a GRAS co-former and so is not likely to 
be considered for a viable drug formulation, the FLU 22-BPY 
(2:1) co-crystal remains useful for benchmarking purposes.
Stability testing in ethyl acetate – competitive slurrying 
experiment 1. The first solution stability test involved slurrying 
of a portion of FLU 22-BPY (2:1) in ethyl acetate, for a period of 
24 h at room temperature, to assess its stability in its initial 
crystallisation medium. The resulting powder was analysed by 
PXRD (Figure ESI-6), and the results are used to assess Decision 
5 of the workflow: is the product material stable to slurrying in 
solution? A few weak peaks correspond to FLU polymorph III 
and may indicate a small amount of dissociation, however there 
is no evidence of 22-BPY and in the main the pattern compares 
well to that obtained for the pure co-crystal. These results 
provide useful information for the future design of scaled-up 
recrystallisation routes that might target particular crystal 
particle attributes, which could retain ethyl acetate as the 
solvent.
Aqueous stability testing – competitive slurrying experiment 2. The 
second solution stability test performed involved slurrying of a 
portion of FLU 22-BPY (2:1) in aqueous conditions, for a period 
of 24 h. This competitive slurrying experiment was performed 
at 37 °C, in an attempt to mimic conditions for dissolution in-
vivo. The resulting powder was again analysed by PXRD (Figure 
ESI-7), which revealed that the co-crystal dissociates into its 
constituent components under these conditions. In this case, 
the answer to Decision 5 is No, with regards to process design, 
but proof of such aqueous dissociation is valuable information 
regarding eventual performance of a drug formulation to be 
delivered orally in tablet form.
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Thermal stability testing. The final test in Stage 4 aims to 
determine the material’s thermal stability, which has 
implications for storage and shelf-life of a potential drug 
formulation and for the design of potential future scale-up 
routes. The conditions for this experiment could vary depending 
on the properties of the sample investigated (e.g. melting 
points, sublimation points, known phase transformations etc.), 
but here a portion of FLU 22-BPY (2:1) co-crystal was placed in 
an oven at 50 °C and portions removed for analysis by PXRD at 
intervals in a 1 week period. The resulting data (Figure ESI-8) 
indicated that the sample is not stable for long under these 
conditions, with dissociation complete after 24 h.
Stage 5: Scale-up by slurrying. Following the positive assessment 
of Decision 5 for slurrying in ethyl acetate, FLU 22-BPY (2:1) can 
be progressed to Stage 5 of the workflow and the potential for 
larger-scale crystallisation via slurrying methods can be 
investigated. In a meso-scale experiment, ca. 1 g of API and co-
former, in a 2:1 ratio, were slurried in the minimum volume of 
ethyl acetate for an extended period. Samples were removed at 
regular intervals and analysed by PXRD (Figure ESI-9). These 
data confirm that a near-pure sample of the co-crystal is formed 
after 1 week, confirming that scale-up by slurrying routes is 
successful for this material. As per the workflow diagram, this 
would be a facile route to achieve the goal of a bulk powder 
sample, where no more complicated control of the particle form 
was required.
Stage 6: Solubility data. In the final stage of the MC-Workflow, 
the successful production of the MC material at a reasonable 
scale also allows determination of solubility data. For a real 
candidate material, determination of the aqueous solubility 
enables an assessment of any improvement in this property for 
the API co-crystal, which may then have implications for its 
usefulness as an alternative drug formulation. The collection of 
gravimetric solubility data for FLU 22-BPY (2:1) was attempted, 
but unfortunately the aqueous solubility level was still very poor 
and it was challenging to obtain accurate g/g mass fractions. As 
such, further analysis is not presented.
3. MC Workflow benchmarking conclusions.
The benchmarking experiments have successfully identified and 
characterised a new MC crystal form of an API material and 
collected additional data that would inform the design of scale 
up experiments in other areas of the CMAC consortium effort. 
These positive outcomes show the usefulness of the workflow 
decision-making process in guiding the research through the 
experiment, ensuring all necessary data are collected in a 
consistent and thorough way.
Benchmarking the Workflows II: Additive control 
of morphology for Isoniazid (IZN)
The additive screening workflow was used to design an additive 
crystallisation route to control the morphology of Isoniazid 
(IZN), an antibiotic commonly used in the treatment of 
tuberculosis. IZN generally crystallises with a needle 
morphology,28 which can cause significant problems for 
downstream processing steps. By introducing additives into the 
crystallisation in very low w/w %, the potential exists to modify 
the resulting morphology of the crystals, towards more 
processable block-like crystal shapes, while minimising the 
likelihood of incorporating the additive into the crystal 
structure. 
1. Workflow inputs/prerequisites.
Initial CSD data mining with ConQuest. Again, it is imperative to 
identify the solid forms of IZN already known and this 
information is readily available in the CSD. In the context of the 
additive workflow, any known MC solid forms can be 
informative for additive selection; where co-crystal formation 
occurs with a particular co-former at high API-to-co-former 
ratios (1:1, 1:2, 2:1 etc), this indicates that this molecule has a 
strong affinity for the API. Thus, if the same material is 
employed as an additive in low concentrations (e.g. ~ 1% wt/wt) 
it follows that some interaction between the API and additive 
may occur. Data mining of IZN structure in the CSD was achieved 
via a structure search using Figure 9, in ConQuest, with the 
following filters employed:
 3D coordinates must be determined
 No polymeric structures
 Only organic structures.
As we require additives to only interact with the API crystal and 
not alter its composition in any way, we are only interested in 
co-crystal hits from the CSD and not salts. As such, explicit 
hydrogen atom assignment was used to preclude the return of 
salt structures for this search.
Figure 9: Structure of Isoniazid target molecule used in ConQuest structure search, 
with all hydrogens explicitly assigned. T2 indicates that the pyridine nitrogen is 
only bonded to two other atoms, precluding the return of pyridinium salt 
structures.
The search returned 68 hits, four of which are determinations 
of the only polymorphic form of IZN published in the CSD at the 
time of searching (CCDC ref-code based: INICAC). We note that, 
during the preparation of this article, a new study reporting the 
discovery of two new metastable polymorphs of IZN has also 
been published.29 The remaining hits are made up of 41 
different MC materials. Of these, the vast majority of API-co-
former interactions involved N…OH or N…COOH hydrogen 
bonds between the pyridine nitrogen atom on IZN and the co-
former.
2. Additive Workflow benchmarking.
Stage 1: Optimisation of non-additive crystallisation parameters. 
Small scale evaporative crystallisation experiments were used 
to optimise the parameters of the basic crystallisation route for 
the API, before additives are introduced to the experiment. We 
note that this stage could also be carried out in other platforms, 
such as cooling, where the necessary equipment is available. For 
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the evaporative screen, 10 mg of API was dissolved in a 
minimum amount of solvent and allowed to slowly evaporate at 
a constant temperature of 40 °C. A small selection of solvents 
was investigated (see Figure ESI-10 for further information).
The resulting materials were analysed by PLM to assess any 
morphology modification. Crystal face-indexing was also 
performed on a representative crystal using SCXRD methods, to 
determine the faces contributing to the crystal morphology. 
These results are then used for later comparison to any additive 
modified samples. Most solvents produced typical needle-like 
IZN crystals as expected, crystals grown from propan-2-ol under 
these conditions formed plate-like morphologies (see Figures 
10 and 11, below). Though plate crystals still present challenges 
for downstream processing stages, this is a step closer to the 
target block morphology and so propan-2-ol was chosen as the 
solvent for further investigation by additive methods. This 
result outlines the benefits of including Stage 1 in the additive 
workflow, as this apparent solvent control effect can now be 
separated from any additive effects on IZN morphology going 
forward.
Stage 2: Selection of suitable additive candidates. This selection 
process was carried out by first utilising the Mercury molecular 
complementarity screening tool discussed above. This tool is 
primarily used for the design of MC materials, however it is also 
a useful aid to identify possible additive candidates; if an API is 
predicted to form a MC material with the target molecule it may 
also, in smaller quantities, have the propensity to interact with 
the growing crystal faces and influence the morphological 
outcome.
For molecular complementarity screening, the GRAS co-former 
library outlined in Table ESI-3 was used, alongside a second 
library of 30 common, not necessarily GRAS, co-formers 
generated from chemicals utilised in our laboratory (Table ESI-
9, ESI). As this study was pursued from an academic perspective, 
the use of non-GRAS additives was less problematic for us as we 
need not be concerned about the potential for incorporation of 
very low levels of additive into the crystal structure. Thus, we 
were able to widen the design space in this way. However, for 
other studies where even the incorporation of a tiny amount of 
additive, or adsorption onto the crystal surface, could be 
problematic, e.g. from an API regulatory perspective, then the 
use of non-GRAS additives should be considered more carefully. 
Full details of the screening searches performed are provided in 
the ESI (Tables ESI-10, ESI-11).
In this case, the results of molecular complementarity searches 
were inconclusive for IZN as screening with both co-former 
libraries returned a large number of hits, even when all five 
molecular descriptors were included. To refine the selection 
further, these hits were cross-referenced with the results of CSD 
data mining in ConQuest to select a sub-set of additives that 
both satisfied molecular complementarity screening and are 
either already known to form co-crystals with IZN, or a co-
crystal is known with a closely related molecule (e.g. structural 
isomers). A final screening step involved consideration of 
Decision 1 of the workflow: Are the chosen additives soluble in 
the solvents used for the optimised non-additive API 
crystallisation?. Small-scale solubility testing with potential 
additives in propan-2-ol, and only those that showed sufficient 
solubility in the chosen crystallisation solvent, and therefore 
satisfying Decision 1, were taken forward
Following this procedure, a set of seven different additives were 
short listed for screening: 3-cyanobenzoic acid, 4-cyanobenzoic 
acid (CSD ref-code TAGNAR), 3-hydroxybenzoic acid (BIDLOP), 
isonicotinamide (EHOWIH), nicotinamide (NICOAM), 3,4-
dihydroxybenzoic acid (WUYNUA) and 3,4-dinitrobenzoic acid 
(YADKOF).
Stage 3: Solubility screening with additives. In the current 
benchmarking study, the choice of propan-2-ol was made on 
the basis of solvent-induced morphology modifications for IZN, 
as described above. Therefore, in reality Stage 3 was bypassed 
for this experiment.
Stage 4: Screening of additive candidates. Small scale evaporative 
crystallisations were set up for the target API with each 
potential additive molecule, using identical conditions to Stage 
1. 10 mg of target molecule with 1% w/w of the additive 
molecule added to each solution. Each crystallisation was then 
allowed to evaporate at a constant temperature of 40 ᵒC for 
several days.
Stage 5: Initial analysis of results. The analysis methods chosen 
will depend on the particle property targeted for control. For 
morphology control, the most useful initial analysis methods 
are PLM, followed by crystal face-indexing via SCXRD methods 
for any promising candidates.
PLM images for both the pure IZN crystallisation in propan-2-ol 
from Stage 1, and the additive screen in Stage 4, are shown in 
Figure 10. Visual analysis of the resulting crystal morphologies 
indicates that there are two promising additive candidates: 3-
hydroxybenzoic (Figure 10(b)) and 3,4-dinitrobenzoic acid 
(Figure 10(h)), while all other crystallisations produced plate 
shaped crystals similar to those observed in the absence of 
additive (Figure 10(a)).
Figure 10: The morphology of IZN crystals from IPA observed in the presence of 
additives. (a) absence of additive, (b) 3-cyanobenzoic acid, (c) 4-cyanobenzoic 
acid, (d) 3-hydroxybenzoic acid, (e) isonicotinamide, (f) nicotinamide, (g) 3,4-
dihydroxybenzoic acid and (h) 3,4-dinitrobenzoic acid.
Face-indexing experiments were then carried out with these 
two candidates, to determine the nature of the morphology 
changes observed. In all cases, indexing of the unit cell 
parameters confirmed that no change in the IZN crystal form 
had occurred on recrystallisation. The results of face-indexing 
analysis can be visualised through the Mercury BFDH 
morphology tool, by generating a suitable morphology input file 
(in CIF format) containing the experimentally-determined 
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crystal face list. The output of this analysis for the IZN additive 
screen is shown in Figure 11.
Figure 11: Crystal faces assigned by experimental face-indexing of IZN single 
crystals from additive screening studies. Left: IZN crystallised from propan-2-ol in 
the presence of 1% 3-hydroxybenzoic acid. Centre: IZN crystallised from propan-
2-ol in the presence of 1% 3,4-dinitrobenzoic acid. Right: IZN crystallised from 
propan-2-ol in the absence of any additives.
Comparison of the observed crystal faces with the underlying 
crystal structure allows us to infer some rationale for 
morphology modification. In general, faces with large areas 
indicate slow growth in the direction perpendicular to that 
face,30 which may indicate that molecules present in solution 
(either additives or solvent) can interact with functional groups 
present at the surface terminations for that face. Similarly, small 
faces indicate fast crystal growth along the perpendicular axis. 
For the plate-like crystals grown from propan-2-ol in the 
absence of additives, the largest faces are the (010) set, 
indicating relatively slow growth in the [010], or b-axis, direction 
in propan-2-ol. In the underlying IZN crystal structure,  𝐶11(8)
one-dimensional chains of IZN molecules, linked by discrete 
NH…N(py) hydrogen bonds, extend parallel to the [010] 
direction (see Figure ESI-11), indicating that crystal growth 
along [010] proceeds via the formation of these interactions. As 
such, the results suggest that propan-2-ol acts to slow the 
formation of these hydrogen bonds, possibly via interaction 
between the alcohol OH groups and the pyridine nitrogen 
atoms on IZN. By contrast, smaller (100) and (001) faces indicate 
faster growth of IZN along the a- and c-axis directions in propan-
2-ol. These correlate with the formation of  chains formed 𝐶(3)
of discrete NH…N interactions between adjacent hydrazine 
moieties along [100], and π-system stacking interactions along 
[001].
For crystals grown in the presence of 3-hydroxybenzoic acid, an 
increase in the area of the (100) faces is observed, leading to a 
more block-like crystal shape. This would indicate slower 
growth in the [100] direction, which may be the result of 
preferential interaction between the additive and IZN 
functional groups at the (100) surface terminations. 
Visualisation of the (100) plane overlaid with the underlying IZN 
crystal structure in Mercury suggests that likely surface 
terminations for the (100) face would expose the hydrazine NH 
groups (Figure 12). We stress that this rationale is an 
approximation, as single crystal data represents the bulk 
structure and provides us with no direct surface chemistry 
information. Instead, we can infer possible real surface 
terminations at the (100) faces (e.g. black dashed lines in Figure 
12) by considering that the (100) plane intersects the NH…N 
hydrogen bonds involving hydrazine, thus a natural cleavage 
point for this face would break these intermolecular 
interactions and expose the hydrazine groups. Here, we assume 
real surface terminations will only break intermolecular 
interactions and covalently bonded molecular species remain 
intact. Thus, from this analysis a potential route for morphology 
modification can be hypothesised; that 3-hydroxybenzoic acid 
can interact with the hydrazine NH groups at the (100) surfaces 
of IZN, thus limiting the growth along [100] and effecting a 
change in the crystal shape
Figure 12: Overlay of the (100) plane (red line) with the underlying bulk IZN crystal 
structure in Mercury. “b” highlights discrete NH…N intermolecular hydrogen 
bonding interactions formed between adjacent hydrazine moieties. The black 
dashed line represents a hypothetical real surface termination for the (100) face, 
assuming only cleavage of intermolecular interactions.
The situation is similar for crystals grown in the presence of 3,4-
dinitrobenzoic acid. Here, the growth is also slowed along the 
[100] direction, in comparison to the plates formed in the 
absence of additive, although the exposed faces are identified 
as the (-101) and (-10-1) sets. Visualisation of these planes 
overlaid with the underlying crystal structure in Mercury (Figure 
ESI-12) also indicate that the hydrazine NH groups are likely to 
be exposed at the surface terminations for these faces, leading 
to a similar rationale for morphology changes.
At this stage of the workflow Decision 3 must be considered: 
Does analysis indicate a change in the targeted property (e.g. 
solid form/morphology/PSD etc) in the presence of each 
additive candidate? As two successful additives have been 
identified in the experiments carried out with IZN, the answer 
to Decision 3 is Yes. Both the 3-hydroxybenzoic acid and the 3,4-
dinitrobenzoic acid experiments can be deemed successful and 
taken through to the next stages of the workflow. The 
remainder of the additives were unsuccessful and can be 
discarded at this point.
Stage 7 onwards. Building on the success of the additive 
discovery stages in this workflow benchmarking study, the final 
stages of IZN additive crystallisation development are still on-
going within the CMAC group. These include the optimisation of 
the API:additive ratio and the design of scaled-up 
crystallisations, aiming towards a viable industrial scale 
crystallisation route. These Stages of the workflow are more 
suited to later stage experimental efforts within the CMAC 
group, and the experiments will be the focus of a subsequent 
publication.
3. Additive Workflow benchmarking conclusions.
The benchmarking experiments have successfully identified two 
additives that can successfully modify the morphology of the 
target API IZN, and the morphology changes have been 
characterised and rationalised by considering the underlying 
crystal structure. These positive outcomes again confirm the 
usefulness of the workflow decision-making process to guide 
the researcher through the experiment and, in particular, 
highlight how implementation of CCDC software tools facilitates 
the decision-making process at all stages of the workflow.
Conclusions
The research presented has shown that the Workflow approach 
provides a logical and structured approach to two important 
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aspects of pharmaceutical materials discovery and primary 
crystalline particle control, contributing to physical property 
optimisation and downstream processability.  The Workflows 
presented are compatible with a reproducible approach to 
process design that harnesses strengths of experimental data 
while also benefiting hugely from informatics-based 
approaches, such as those available in the CSD, to enhance their 
value. 
Critical to the Workflows discussed here, these early 
interventions at the primary particle stage (the initial solid form 
crystallisation) can, in the context of pharmaceutical 
manufacturing, reduce process steps, minimise downstream 
processing, allow for efficient process design by focusing on 
optimised primary solid form and primary particle control, and 
allow for design of optimised particle properties. Efficient 
methods for evaluating the potential efficacy of such process 
steps are vital, as these (here, MC crystals and use of additives) 
are often considered as “additional options” that may not be a 
first choice for process development but which may give key 
benefits if assessed fully at an early stage.
These Workflows place rational early stage crystallisation 
design at the heart of end-to-end process design and 
integration, potentially allowing for the reduction of 
experimental screening by establishing effective digital / 
informatics-based approaches and allowing multi-component 
materials and additive design to take processing and regulatory 
requirements fully into account. The Million-plus structures and 
associated tools available within the CSD can play a substantial 
role in such efforts.
Integrating these capabilities into automated digital-driven 
workflow assessment and the creation of end-to-end processes 
is a key future aim of the CMAC consortium, to which the 
presented Workflow developments are contributing.
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Figure 1: CMAC Multicomponent (MC) material screening workflow. The workflow is driven by the decision points as indicated in the text; these capture the key 
elements indicating if the co-crystallisation process is likely to have value. Light blue squares indicate points at which the CCDC software tools are implemented.  Decision 
1: Is crystallinity retained following evaporation?; Decision 2: Is there evidence for a new product from the PXRD and DSC analysis?; Decision 3: Are there single crystals 
formed from the evaporation?; Decision 4: Is there good diffraction from the single crystal and can a structure be solved?; Decision 5: Is the product material stable to 
slurrying in solution?; Decision 1a: Is crystallinity retained after grinding?; Decision 2a: Is there evidence for a new product from the PXRD and DSC analysis?; Decision 
3a: Is the new product pure, or is there a mixture of product and starting materials present?
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Figure 2: CMAC Additive screening workflow. The workflow is driven by the decision points as indicated in the text; these capture the key elements indicating if the use of additive 
crystallisation methods is likely to have value.  Light blue squares indicate points at which the CCDC software tools are implemented.  Decision 1: Are the chosen additives soluble in 
the solvents used for optimised non-additive API crystallisation process? (i.e. can a co-solvent be found easily?); Decision 2: Does the API solubility / MSZW remain the same in the 
presence of each additive candidate?; Decision 3: Does the analysis indicate a change in targeted property (e.g. solid-form / morphology / PSD etc.) in the presence of each additive 
candidate?; Decision 4: Does the crystallisation process chosen for the product proceed unchanged following a change in additive ratio?
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Figure 3: Structure of flufenamic acid (FLU), used as structure search in ConQuest, 
with all hydrogens explicitly assigned.
Figure 4: Initial analysis of [FLU + 22-BPY] evaporative crystallisation screening 
experiment. (a) Comparison of experimental PXRD data for sample with predicted 
PXRD patterns of starting materials (FLU Polymorph III and 22-BPY) from CSD 
structure data. (b) Comparison of experimental DSC data for sample with starting 
material melting point data from literature (grey dashed line = 22-BPY melting 
point, red dashed line = FLU melting point).
Figure 5: Initial analysis of [FLU + BA] evaporative crystallisation screening 
experiment. (a) Comparison of experimental PXRD data for sample with predicted 
PXRD patterns of starting materials (FLU Polymorph III and BA) from CSD structure 
data. (b) Comparison of experimental DSC data for sample with starting material 
melting point data from literature (grey dashed line = BA melting point, red dashed 
line = FLU melting point).
Figure 6: Single crystal X-ray structure of FLU 22-BPY (2:1) co-crystal, showing the 
atomic connectivity with ellipsoids shown at 50 % probability. The CF3 moiety is 
disordered and is modelled over two positions, though the second component is 
omitted here for clarity. Labelled atoms are included in the asymmetric unit, with 
the remaining structure is generated by symmetry. Red dashed lines indicate 
hydrogen bonding interactions.
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Table 1: Single crystal X-ray diffraction data for FLU 22-BPY (2:1) co-crystal
Sample FLU 22-BPY (2:1)
Empirical formula C19H14F3N2O2
Formula weight 359.32
Temperature/K 150.00(10)
Crystal system monoclinic
Space group P21/c
a/Å 9.6550(8)
b/Å 7.8337(4)
c/Å 21.8957(16)
α/° 90
β/° 100.355(7)
γ/° 90
Volume/Å3 1629.1(2)
Z 4
ρcalcg/cm3 1.465
μ/mm-1 0.119
F(000) 740.0
Crystal size/mm3 0.61 × 0.45 × 0.05
Radiation Mo Kα (λ = 0.71073)
2Θ range for data collection/° 6.208 to 51.362
Reflections collected 7063
Independent reflections 3095 [Rint = 0.0649, Rsigma = 0.1083]
Data/restraints/parameters 3095/43/256
Goodness-of-fit on F2 1.009
Final R indexes [I>=2σ (I)] R1 = 0.0585, wR2 = 0.0853
Final R indexes [all data] R1 = 0.1393, wR2 = 0.1106
Largest diff. peak/hole / e Å-3 0.28/-0.24
Figure 7: Initial analysis of [FLU + 22-BPY] mechanochemical crystallisation 
screening experiment. (a) Comparison of experimental PXRD data for 15 min 
ground sample with predicted PXRD patterns of starting materials (FLU Polymorph 
III and 22-BPY) from CSD structure data. (b) Comparison of experimental DSC data 
for 15 min ground sample with starting material melting point data from literature 
(grey dashed line = 22-BPY melting point, red dashed line = FLU melting point).
Figure 8: Formation of near-pure FLU 22-BPY (2:1) co-crystal by mechanochemical 
crystallisation methods with extended grinding times. Peaks associated with the 
22-BPY starting material are most obvious and are seen to decrease in intensity as 
grinding time increases, with no evidence of starting material after 60 min.
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Figure 9: Structure of Isoniazid target molecule used in ConQuest structure search, 
with all hydrogens explicitly assigned. T2 indicates that the pyridine nitrogen is 
only bonded to two other atoms, precluding the return of pyridinium salt 
structures.
Figure 10: The morphology of IZN crystals from IPA observed in the presence of additives. (a) absence of additive, (b) 3-cyanobenzoic acid, (c) 4-cyanobenzoic acid, (d) 
3-hydroxybenzoic acid, (e) isonicotinamide, (f) nicotinamide, (g) 3,4-dihydroxybenzoic acid and (h) 3,4-dinitrobenzoic acid.
Figure 11: Crystal faces assigned by experimental face-indexing of IZN single 
crystals from additive screening studies. Left: IZN crystallised from propan-2-ol in 
the presence of 1% 3-hydroxybenzoic acid. Centre: IZN crystallised from propan-
2-ol in the presence of 1% 3,4-dinitrobenzoic acid. Right: IZN crystallised from 
propan-2-ol in the absence of any additives.
Figure 12: Overlay of the (100) plane (red line) with the underlying bulk IZN crystal 
structure in Mercury. “b” highlights discrete NH…N intermolecular hydrogen 
bonding interactions formed between adjacent hydrazine moieties. The black 
dashed line represents a hypothetical real surface termination for the (100) face, 
assuming only cleavage of intermolecular interactions.
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